Can a new drug regimen beat the standard for stem cell transplant complications?
Disease control
Ongoing
This trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…
Phase 3 • Sponsor: DKMS gemeinnützige GmbH • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC